Table 5.
Univariate and multivariate Cox regression analyses of PFS in SCLC patients
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Sex | ||||||
| Male vs. Female | 1.121 | 0.486-2.585 | 0.788 | - | - | - |
| Age | ||||||
| >60 vs. ≤60 | 0.727 | 0.349-1.518 | 0.396 | - | - | - |
| Smoking | ||||||
| Yes vs. No | 0.653 | 0.304-1.403 | 0.275 | - | - | - |
| ECOG PS | ||||||
| 2 vs. 0-1 | 1.331 | 0.582-3.045 | 0.498 | - | - | - |
| Stage | ||||||
| IV vs. II-III | 2.849 | 1.297-6.261 | 0.009** | 2.438 | 1.090-5.452 | 0.030* |
| No. of metastases | ||||||
| ≥2 vs. 0-1 | 2.259 | 0.896-5.697 | 0.084 | - | - | - |
| CNS metastasis | ||||||
| Yes vs. No | 0.251 | 0.057-1.102 | 0.067 | - | - | - |
| liver Metastasis | ||||||
| Yes vs. No | 0.581 | 0.217-1.557 | 0.280 | - | - | - |
| Treatment response | ||||||
| SD+PD vs. CR+PR | 2.933 | 1.390-6.190 | 0.005** | 2.209 | 1.007-4.845 | 0.048* |
| Baseline VEGF-A (pg/mL) | ||||||
| >338.5 vs. ≤338.5 | 5.397 | 2.183-13.340 | <0.001** | 3.443 | 1.330-8.908 | 0.011* |
| Baseline SII (×109/L) | ||||||
| >720 vs. ≤720 | 2.134 | 0.982-4.636 | 0.056 | - | - | - |
Abbreviations: CI: confidence interval; CNS: central nervous system; CR: complete response; ECOG PS: eastern cooperative oncology group performance status; HR: hazard ratio; PD: progressive disease; PFS: progression-free survival; PR: partial response; SCLC: small cell lung cancer; SD: stable disease; SII: systemic immune-inflammation index; VEGF-A: vascular endothelial growth factor A; *P<0.05; **P<0.01.